Evaluation and use of biomarkers for the detection and monitoring of diseases and their treatment

Design and conduct clinical and non-clinical pharmacological trials to evaluate the efficacy and safety of active ingredients, medical devices and innovative therapies including Human Corporeal Material (HCM).

Personalization of treatments

• Study biomarkers and various factors (e.g. genetic factors and metagenomics) enabling drug treatments and HCM transfers to be tailored to individual patient needs (personalized medicine).

Translational research

• Translate discoveries from basic research into pharmacological applications enabling the development of new treatments for diseases or their diagnosis.

Studying drug risks using biomarkers (pharmacovigilance)

• Designing and developing pharmacological analyses and studies enabling the detection, assessment, understanding and prevention of adverse effects or any other problems related to drugs or their metabolism by the intestinal microbiota.

Optimizing the design of pharmacokinetic and pharmacodynamic (comparability) studies using modeling, simulation and artificial intelligence tools

• Optimizing the evaluation criteria of pharmacokinetic and pharmacodynamic studies in several contexts including bioequivalence assessment, drug-drug interactions, dose optimization and adjustment in pediatric populations, in orphan diseases, special clinical situations such as immunodepression or old age etc., thus guaranteeing efficacy and safety. guaranteeing the efficacy and safety of therapeutic interventions.

Evaluation of existing therapies

Evaluate the efficacy of existing treatments and propose improvements where necessary.

Regulatory science

• Development of methods and studies relating to issues associated with the evaluation of drugs and the use of HCM

Optimization of methods for the post-market evaluation of drugs and HCM

• Development of tools for the quantitative analysis of the benefit/risk balance of drugs by integrating the different types of data available. This will include the integration of post-marketing surveillance data on side effects.

Therapeutic adherence studies

• Evaluate patient adherence to treatments and propose solutions to improve compliance.
• Developing studies to characterize patient preferences (e.g. Discrete Choice Experiment) with a view to increasing therapeutic adherence

Conducting synthesis studies (meta-analysis type) to synthesize data from the literature for which individual studies have not provided a conclusive answer.

Evaluation of environmental toxicology of drug or medical origin.

To be part of the monitoring of environmental pollution induced by treatments or medical practice and which may affect Public Health.

Multidisciplinary collaboration

Work closely with researchers, physicians, pharmacists, nurses and other healthcare professionals to carry out clinical investigations.

Biocompatibility assessment of new medical devices

Investigation of toxicity induced by implantable biomaterials used in a medical setting.

Training and education

Training healthcare professionals in the latest advances in clinical pharmacology and best clinical practices.

Participation in continuing education for doctors, pharmacists, nurses and other care providers who have contact with the drug.

Preferred point of contact for communication administration when contacted by the media on drug-related issues. The teams will share questions and interviews in order to enhance the visibility of the institution and the expertise of its academics.

Advice to regulatory authorities

Collaborate with regulatory agencies to contribute to the approval of new drugs and the regulation of existing drugs.

Make the expertise of the research unit's academics and researchers contractually available to the FAMHP and federal research organizations (e.g. Sciensano)"